Baxter International now in full-scale production of a commercial A/H1N1 vaccine

Baxter International announced that it “has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology.” Baxter said it received an A/H1N1 strain from the U.S. CDC in early May and “is diligently working to deliver a pandemic vaccine for use as early as July.” Baxter noted that “a number of national public health authorities have existing pandemic agreements with Baxter that allow them to place orders for a vaccine now that a pandemic has been declared by WHO.” These public health authorities will be evaluating their needs to determine their orders for vaccine supply. Baxter said that despite its “existing obligations to supply vaccine under a pandemic phase 6 alert, Baxter is also committed to working with WHO to allocate a portion of the company’s commercial production to address global public health issues deemed most urgent.”

(BUSINESS WIRE, 12 June 2009)

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.